US 12,167,998 B2
Spiro-lactam NMDA receptor modulators and uses thereof
John A. Lowe, III, Stonington, CT (US); and M. Amin Khan, Evanston, IL (US)
Assigned to Tenacia Biotechnology (Hong Kong) Co., Limited, Hong Kong (CN)
Filed by Tenacia Biotechnology (Hong Kong) Co., Limited, Sheung Wan (HK)
Filed on Jun. 24, 2021, as Appl. No. 17/357,064.
Application 17/357,064 is a continuation of application No. 16/536,582, filed on Aug. 9, 2019, granted, now 11,077,094, issued on Aug. 3, 2021.
Application 16/536,582 is a continuation of application No. 15/969,200, filed on May 2, 2018, granted, now 10,441,572, issued on Oct. 15, 2019.
Application 15/969,200 is a continuation of application No. 15/337,605, filed on Oct. 28, 2016, granted, now 10,052,308, issued on Aug. 21, 2018.
Application 15/337,605 is a continuation of application No. 14/764,395, granted, now 9,512,134, issued on Dec. 6, 2016, previously published as PCT/US2014/013619, filed on Jan. 29, 2014.
Claims priority of provisional application 61/757,903, filed on Jan. 29, 2013.
Prior Publication US 2022/0151992 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/397 (2006.01); A61K 31/407 (2006.01); C07D 487/10 (2006.01)
CPC A61K 31/397 (2013.01) [A61K 31/407 (2013.01); C07D 487/10 (2013.01)] 2 Claims
OG exemplary drawing
 
1. A method of treating post traumatic stress disorder, the method comprising:
administering to a patient in need thereof a therapeutically effective amount of a compound represented by:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt and/or a stereoisomer thereof.